Oslo Cancer Cluster shared a post on LinkedIn:
“On the occasion of ESMO – European Society for Medical Oncology 2025, Oslo Cancer Cluster and partners Oslo universitetssykehus, Nor Trials, Swe Trial, Karolinska Institutet, Lif – de forskande läkemedelsföretagen, Legemiddelindustrien (LMI), and Vision Zero Cancer, Testbed Sweden Precision Health Cancer hosted a breakfast symposium at Felleshus Nordic Embassies Berlin.
A full house gathered on 17 October to explore how collaboration across Europe can accelerate the next era of cancer innovation – from precision medicine to radiopharmaceuticals and ATMPs.
The symposium brought together leaders from research, healthcare, industry, policy, and patient advocacy to discuss three key themes shaping the future of cancer care:
- Precision cancer medicine at scale.
- Radiopharmaceuticals as a competitiveness play.
- ATMPs from vision to implementation.
Here’s a look back at some moments from the event, and a summary of the highlights.
A heartfelt thank you to all the speakers and panel participants for sharing their valuable insights and inspiring discussions.”
More posts about the Oslo Cancer Cluster on OncoDaily.
